U-M to conduct clinical trial to test AstraZeneca COVID-19 vaccine

Author | Kelly Malcom

Michigan Medicine is partnering with the pharmaceutical company AstraZeneca for a Phase 3 clinical trial to test a vaccine against COVID-19. The AZD1222 COVID-19 VACCINE Study will research an investigational vaccine for the prevention of COVID-19, the disease caused by the new coronavirus (SARS-CoV-2).

The study will look at how well the investigational vaccine works and how safe it is. U-M will begin recruiting hundreds of participants for the trial immediately, until the trial is full. U-M is one of several U.S. sites supporting the AstraZeneca trial, with the aim of including 30,000 individuals over a period of two years.

“The importance of a safe and effective vaccine against COVID-19 cannot be overstated. The AstraZeneca Phase III trial will bring answers as to the effectiveness of this vaccine. At the end of the day, this kind of rigorous clinical trial with the commitment of Michigan Medicine and other study sites to safety will be a key step in realizing a vaccine that will save lives when one is developed,” says Marschall Runge, M.D., Ph.D., Dean, U-M Medical School, Executive Vice President, Medical Affairs and CEO, Michigan Medicine.

The AstraZeneca trial is one of several vaccine trials being funded through a public/private partnership under the U.S. Department of Health and Human Services called Operation Warp Speed. It is designed to accelerate the development of a life-saving vaccine to prevent COVID-19, while maintaining standards for safety and efficacy.

“We are proud to advance the University of Michigan's outstanding legacy of excellence in vaccine trials with this important clinical trial partnership. We hope one day soon to be able to announce a successful vaccine against COVID-19 and save lives,” says Mark Schlissel, M.D., Ph.D., president of the University of Michigan.

Phase I/II trials of the vaccine in more than 1000 people were completed earlier this year and demonstrated increased antibody responses against SARS-CoV-2 and no serious adverse effects.

For more information about the study, visit https://www.uofmhealth.org/covid19-vaccine or email [email protected].

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Featured News & Stories
Health Lab
Protecting heart health during pregnancy
Experts discuss pregnancy and heart health.
woman holding blackboard sign and poster next to her in purple
Health Lab
A mother’s tragedy leads to a new resource for grieving parents
Created by a patient and grieving parent, a peer and medically reviewed guidebook on pregnancy and infant loss offers others going through the same experience more resources during the difficult time.
kidneys blue yellow
Health Lab
Why personalized medicine is important in rare kidney disease
Building a comprehensive human kidney cell and tissue catalog could help develop more treatments for kidney disease.
10 year old boy leaning against tree and posing with his mom and sisters outside
Health Lab
Family travels over 1,000 miles for son’s heart transplant
Family travels over 1,000 miles for son's heart transplant and ongoing heart care
Scientific illustration of gliobastoma cells in the brain
Health Lab
Path forward for glioblastoma treatment
Experts in brain cancer outline current discoveries and offer a path of hope for glioblastoma treatment
Health Lab Podcast in brackets with a background with a dark blue translucent layers over cells
Health Lab Podcast
Period Poverty and the Need to Make Menstruation Products Easier to Access
A survey focused on how much people in their teens and early 20s know about periods and their experience and attitudes around “period poverty”.